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INTRODUCTION
Cell cycle progression is governed by cell cycle regulators
such as cyclins and cyclin-dependent kinases (cdks). Dysregu-
lated expression of these cyclins, cdks, or both is involved in
uncontrolled cell growth and malignant transformation (1).
Individual cyclins act at different phases of the cell cycle by
binding and activating corresponding cdks. Under normal
conditions, cyclins undergo degradation at the end of each
functional phase, whereas the level of cdks remains invariable
throughout the cell cycle (2, 3). Cyclin B1, which activates
cdc2 and regulates progression of cell cycle through G2 and
M phases, is recently focused as a subject to be studied. Newly
synthesized cyclin B1 binds to the inactive cdc2 at the begin-
ning of G2 phase forming a cyclin B1/cdc2 complex, which
can be activated by phosphorylation. This activated kinase
complex then phosphorylates a number of proteins important
in regulating the G2 to M transition (4). Overexpression of
cyclin B1 and cdc2 has been reported in malignancies of breast
(5), colon (6), esophagus (7), liver (8), and so on. According
to recent studies, p53 regulates G2 checkpoint through repres-
sion of cyclin B1 and cdc2 transcription (9). In this study, the
authors examined the expression of cyclin B1 and cdc2 along
with p53 and Ki-67 in 68 cases of nodal non-Hodgkin’s lym-
phoma by immunohistochemical method and analyzed the
correlation of the expression of cyclin B1 and cdc2 with various
clinicopathologic findings including response to chemotherapy
andoverall survival.
MATERIALS AND METHODS
Study population
Sixty-eight cases of histologically diagnosed nodal non-
Hodgkin’s lymphomas from 1987 to 1998 at Hanyang Uni-
versity Medical Center were submitted for this study. Follow-
up data of the cases were retrieved from clinical records of the
hospital retrospectively. The classification and diagnoses of
malignant lymphoma were made based on the new World
Health Organization classification of lymphomas (10). The
staging of nodal non-Hodgkin’s lymphoma was performed
according to the Ann Arbor staging system (11).
The patients were grouped as complete remission, partial
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Expression of Cyclin B1 and cdc2 in Nodal Non-Hodgkin's 
Lymphoma and its Prognostic Implications
To investigate the role of cyclin B1 and cdc2 in the pathogenesis and progression
of malignant lymphoma, 68 cases of nodal non-Hodgkin’s lymphoma were exam-
ined about the expression of cyclin B1 and cdc2 along with p53 and Ki-67 by
immunohistochemical method. The correlation of their expression with various
clinicopathologic findings was also analyzed. Cyclin B1 and cdc2 were diffusely
expressed in 39 cases (57.4%) and 54 cases (79.4%) out of 68 cases studied,
respectively. The mean labeling indices of cyclin B1 and cdc2 in malignant lym-
phoma were 31.9% and 68.0%, respectively. In normal lymphoid tissues, cyclin
B1 and cdc2 were expressed predominantly in the germinal center with mean
labeling indices of 13.9% and 28.3%, respectively. The correlation between the
expression of cyclin B1 and cdc2 was noted (p=0.013). The expression of Ki-67
was correlated with that of cyclin B1 (p=0.023) and marginally correlated with that
of cdc2 (p=0.056). The expression of cdc2 and p53 in complete remission group
to chemotherapy was lower than that of progressive disease group (p=0.047,
p=0.049). In multivariate analysis, the clinical stage alone showed significance
on overall survival (p=0.049). In conclusion, cyclin B1 and cdc2 appeared to be
involved in the genesis or progression of malignant lymphoma and cdc2 can be
a useful marker for response to  chemotherapy. 
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Accepted : 8 March 2002remission, progressive disease, and stable disease according
to chemotherapy response. As control, 10 cases of reactive
hyperplasia of lymph nodes and tonsils were used. 
Immunohistochemical staining
Paraffin-embedded, 4  m-thick tissue sections were select-
ed for immunohistochemistry. Slides were dehydrated, depa-
raffinated through xylene, and then rehydrated through grad-
ed alcohols. To retrieve the antigenicity, the sections were
treated with microwaves in 10 mM citrate buffer at pH 6.0
for 30 min. Then the sections were immersed in methanol
containing 2% H2O2 for 30 min to block the endogenous
peroxidase activity and pretreated with normal goat serum
to reduce nonspecific reactions. The sections were incubated
at 4℃ overnight with each primary antibody. The primary
antibodies used were cyclin B1 (Novocastra, Newcastle, U.K.,
1:20), cdc2 (Santa Cruz, CA, U.S.A. 1:100), p53 (Novocas-
tra, 1:50), and Ki-67 (Biogenex, San Ramon, CA, U.S.A.
1:50). Immunohistochemical staining was performed using
standard streptavidin-biotin complex procedure. 3,3′ -diami-
nobenzidine was used as a chromogen, and Meyer’ s hema-
toxylin was used for counterstaining. In case of malignant
lymphoma, after three representative areas were photographed
under ×200 magnification, the numbers of entire cell and
positively stained cell were counted to assess the expression
of cyclin B1, cdc2, p53, and Ki-67. On immunostaining for
cyclin B1 and cdc2, cytoplasmic and/or nuclear staining were
considered positive. Whereas, only nuclear staining was con-
sidered positive on immunostaining for p53 and Ki-67. Posi-
tive staining in more than 5% of the tumor cells was consid-
ered positive. In case of normal lymphoid tissue, three rep-
resentative areas were photographed under 200 magnifica-
tionin germinal center and interfollicular area, respectively.
Statistical analysis
The relationships between expression of cyclin B1, cdc2,
p53, Ki-67 and various clinicopathological findings were
evaluated using  2 test and Kruskal-Wallis test. The Pearson
correlation and paired two-tailed Student’s t-test were used to
examine the associations between the expression of cyclin B1,
cdc2, p53, and Ki-67. Kaplan-Meier survival curves were made
to assess whether any level of cyclin B1 and cdc2 had any
effect on overall survival of patients with malignant lym-
phoma and the resulting curves were compared using the log-
rank test. Cox’s proportional hazards regression model was used
as multivariate analyses to find significant independent prog-
nostic markers. 
A value less than 0.05 was considered to be statistically
significant. These statistical analyses were performed with
SPSS for Windows (version 7.5).
RESULTS
Clinical data
The clinical data of the patients with malignant lymphoma
are summarized in Table 1. Of 68 cases, 42 were men and 26
were women. The age ranged from 4 to 78 yr, with a mean
age of 45.8 yr. The follow-up period ranged from 1 month to
113 months. The median follow-up period was 23.4 months.
According to the chemotherapeutic response, the patients
were grouped as complete remission (n=22), partial remis-
sion (n=6), stable disease (n=3), and progressive disease (n=
11). There were 5 cases with stage I, 11 cases with stage II,
12 cases with stage III, and 26 cases with stage IV. Stage was
not confirmed in the remaining 14 cases due to data loss. The
histologic subtypes included diffuse large B-cell lymphoma
(DLBL, n=35), follicular lymphoma (FCL, n=5), lymphoblas-
tic lymphoma (LB, n=7), Burkitt’s lymphoma (n=6), periph-
eral T-cell lymphoma (PTCL, n=10), anaplastic large cell lym-
phoma (ALCL, n=3), angioimmunoblastic T-cell lymphoma
(AILD, n=1), and extranodal NK/T cell lymphoma (n=1). 
Expression of cyclin B1 and cdc2 in normal lymphoid
tissues
The staining pattern of cyclin B1 and cdc2 exhibited definite
regional differences in normal lymphoid tissues (Fig. 1). The
germinal center was characteristically highlighted. On the
other hand, mantle zone and parafollicular T-cell zone were
negligible. Cyclin B1 and cdc2 were expressed mainly in the
cytoplasm, and sometimes in the nuclei. The labeling indices
of cyclin B1 were 13.9%, 0.8%, and 1.2% in germinal cen-
ter, mantle zone, and parafollicular T-cell zone, respectively.
The labeling indices of cdc2 were 28.3%, 1.3%, and 2.1% in
germinal center, mantle zone, and parafollicular T-cell zone,
respectively. Ki-67 and p53 were detected in the nuclei of
germinal center cells. In the mantle and parafollicular T-cell
zone, the positive cells were rare.
Expression of Cyclin B1 and cdc2 in Malignant Lymphoma 323
Sex   Male 42
Female 26
Age (yr)  4-78 (mean, 45.8)
Clinical follow-up duration(months) 1-113 (mean, 23.4)
Response to chemotherapy
Complete remission 22
Partial remission 6
Stable disease 3
Progressive disease 11
Ann Arbor stage    I 5
II 11
III 12
IV 26
Undetermined 14
Table 1. Clinical data of 68 cases with nodal non-Hodgkin's
lymphoma324 Y.H. Jin, C.K. Park
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Expression of cyclin B1, cdc2, p53, and Ki-67 in nodal
non-Hodgki’s lymphoma
Cyclin B1 and cdc2 were diffusely expressed in 39 cases
(57.4%) and 54 cases (79.4%) of 68 cases with malignant
lymphomas, respectively (Fig. 2A, B). The mean labeling
indices of cyclin B1 and cdc2 were 31.9% and 68.0%, re-
spectively. The intracellular localization of immunostaining
in malignant lymphomas were not different from those of
normal lymphoid tissues. The immunostaining of cyclin B1
and cdc2 was detected predominantly in the cytoplasm. There
was no statistically significant difference in cyclin B1 and
cdc2 expression according to histologic types (Table 2). Cyclin
B1 and cdc2 showed no correlation with age, sex, and stage.
Cdc2 showed lower expression in complete remission group
compared to the expression in progressive disease group,
which was statistically significant (p=0.047) (Fig. 3). 
p53 was expressed diffusely in 22 cases (32.4%) (Fig. 2C).
Ki-67 was expressed diffusely in all cases, with a mean pro-
liferative index of 35.7% (Fig. 2D). Like normal lymphoid
tissues, the nuclei showed positive immunostaining against
p53 and Ki-67. p53 showed high expressions in anaplastic
large cell lymphoma and angiocentric lymphoma, but the
difference was not statistically significant (Table 2). p53 and
Ki-67 showed no correlation with age, sex, and stage. p53
showed a lower expression in complete remission group than
Age 2.437 0.997-1,034 0.094
Sex 0.894 0.645-3.333 0.361
Stage 3.850 0.936-1.827 0.049*
Cyclin B1 0.237 0.984-1.025 0.678
Cdc2 0.144 0.989-1.013 0.868
p53 0.358 0.699-1.458 0.959
Ki-67 2.089 0.981-1.023 0.870
*: Statistically significant. Cox proportional hazards regression model is
as follows: h1(t)=h0(t) exp ( 1 age group+ 2 sex+ 3 stage group+ 4
cyclin B1+ 5 cdc2+ 6 p53+ 7 Ki-67). Regression analysis was per-
formed using forward stepwise method. Age: 0=<60, 1=>60; Sex: 0=
male, 1=female; Stage group: 0=stage I/II, 1=stage III/IV; Cyclin B1: 0=
negative, 1=positive; Cdc2: 0=negative, 1=positive; p53: 0=negative,
1=positive; Ki-67: 0=negative, 1= positive. 
Factor Hazard ratio 95% confidence interval p value
Table 3. Multivariate Cox regression analysis for individual
parameters
DLBL (n=35) 20 (57.1%) 27 (77.1%) 12 (34.3%)
FCL (n=5) 3 (60%) 5 (100%) 1 (20%)
LB (n=7) 4 (57.1%) 6 (85.7%) 0
Burkitt (n=6) 3 (50%) 6 (100%) 2 (33.3%)
PTCL (n=10) 6 (60%) 6 (60%) 4 (40%)
ALCL (n=3) 2 (66.7%) 2 (66.7%) 2 (66.7%)
AILD (n=1) 1 (100%) 1 (100%) 0
Extranodal (n=1) 0 1 (100%) 1 (100%)
DLBL, diffuse large B-cell lymphoma; FCL, follicular lymphoma; LB, lym-
phoblastic lymphoma; Burkitt, Burkitt's lymphoma; PTCL, peripheral T-
cell lymphoma; ALCL, anaplastic large cell lymphoma; AILD, angioim-
munoblastic T-cell lymphoma; Extranodal, extranodal NK/T cell lym-
phoma.
Type Cyclin B1 (%) cdc2 (%) p53 (%)
Table 2. Percentages of cyclin B1, cdc2, and p53 expres-
sions in 68 cases of nodal non-Hodgkin's lymphoma accord-
ing to histologic types
Fig. 1. Immunostating for cyclin B1 and cdc2 in the reactive tonsil (×200). Cyclin B1 (A) and cdc2 (B) are expressed predominantly
in germinal center cells. whereas mantle cells and interfollicular small lymphocytes are almost negative.in progressive disease group, which was statistically signifi-
cant (p=0.049). 
Correlations between cyclin B1, cdc2, p53, and Ki-67
immunostaining in nodal non-Hodgkin’s lymphoma
The expression of cyclin B1 had a tendency to increase ac-
cording to that of cdc 2, which was statistically significant
(p=0.013). Cyclin B1 showed a significant correlation with
Ki-67 (p=0.023). Cdc2 and Ki-67 showed a marginally signifi-
cant correlation (p=0.056). However, p53 was not correlated
with cyclin B1, cdc2, or Ki-67.
Survival analysis
Survival analysis was performed in 60 patients with a mean
observation duration of 23.4 months. Cyclin B1, cdc2, and
p53 showed no significant difference in survival regardless
of the cut-off value in the Kaplan-Meier survival curves (Fig.
4). On multivariate analysis, the stage alone was a significant
variable affecting overall survival (Table 3). Cyclin B1, cdc2,
and p53 had no influence on the overall survival. 
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Fig. 2. Immunostaining for cyclin B1 (A), cdc2 (B), p53 (C), and Ki-67 (D) in the case of diffuse large B-cell lymphoma (×400). Cyclin
B1 (A) and cdc2 (B) are diffusely expressed in the cytoplasm of lymphoma cells, whereas p53 (C) Ki-67 (D) are diffusely expressed in
the nuclei of lymphoma cells.
A B
C DDISCUSSION
To evaluate the role of cyclin B1/cdc2 in the pathogenesis
of malignant lymphoma and to determine whether the over-
expression of cyclin B1/cdc2 influences the prognosis includ-
ing response to chemotherapy and overall survival, the authors
studied the aberrant expression of cyclin B1 and cdc2 in 68
patients with nodal non-Hodgkin’s lymphomas. 
In this immunohistochemical study, the mean labeling
indices of cyclin B1 and cdc2 in malignant lymphomas were
31.9% and 68.0%, respectively. The mean labeling indices
of cyclin B1 and cdc2 in the germinal center of normal lym-
phoid tissues were 13.9% and 28.3%, respectively, which
are much lower than those of malignant lymphomas. The
staining patterns between malignant lymphomas and reactive
lymphoid tissues were quite different. In reactive lymphoid
tissues, the staining pattern showed a regional difference, that
is, only germinal centers were highlighted. In contrast, cyclin
B1 and cdc2 were expressed diffusely in malignant lympho-
mas. These results suggest that cyclin B1 and cdc2 may play
a role in the genesis or progression of malignant lymphoma.
How cyclin B1 and cdc2 participate in tumor progression
remains unknown. Although it has been revealed that p53
plays a role in arrest at G1 checkpoint through p53-mediat-
ed synthesis of the cell cycle inhibitor, p21, recent studies
revealed that p53 regulates G2 checkpoint in the cell cycle
by inactivating cdc2 kinase (9, 12). This inactivation of cdc2
kinase results, at least in part, from repression of cyclin B1
and cdc2 transcription. However, enforced expression of both
cyclin B1 and cdc2 leads to an override of p53-mediated G2-
M arrest. Because p53 mutation has been found in a variety
of malignancies (13, 14), p53 dysregulation may result in a
failure of repression of cyclin B1 and cdc2, which may cause
overexpression of cyclin B1/cdc2 and G2-M transition with-
out G2 checkpoint or without genomic integrity. On the other
hand, because constitutive activation of cyclin B1-associated
cdc2 kinase overrides p53-mediated cell cycle arrest, cell cycle
can continue without G2 checkpoint in case cyclin B1 is over-
expressed. Cyclin B1 overexpression may be caused by im-
paired proteolytic degradation, unlimited protein synthesis,
or by some other reasons. It remains to be elucidated how the
overexpression of cyclin B1 and cdc2 is involved in onco-
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Fig. 3. Results of cdc2 expression according to chemotherapy
response. When the complete remission group is compared to
the progressive disease group, cdc2 shows lower expression in
the former group with a statistical significance (p=0.047). 
SD: stable disease, PR: partial remission, PD: Progressive dis-
ease, CR: Complete remission.
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Fig. 4. Kaplan-Meier survival curve stratified according to the extent of cyclin B1 (left) and cdc2 (right) expressions. When the expression
of cyclin B1 is stratified as 30% or more (n=9) and below 30% (n=30), the survival curve of cyclin B1 shows no significance (left). When
the expression of cdc2 is stratified as 30% or more (n=41) and below 30% (n=13), the survival curve of cdc2 shows no significance.
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Although there was no significant correlation between the
expression of p53 and cyclin B1/cdc2 in this study, more stud-
ies are needed to assess the relation between p53 and cyclin
B1/cdc2 in malignant lymphoma. Cyclin B1 is normally pre-
sent only in the later cell cycle phases and re-synthesized as
late as the beginning of the S phase, whereas cdc2 is expressed
during all phases of the cell cycle except G0 phase (4). This
fact can be the reason why the labeling index of cdc2 is higher
than that of cyclin B1 in both reactive lymphoid tissue and
malignant lymphoma. 
Although overexpression of cyclin B1 has been shown to be
an important factor affecting survival in several malignant
diseases including esophageal squamous cell carcinoma (7),
non-small cell lung cancer (15), and hepatocellular carcino-
ma (8), cyclin B1 and cdc2 showed no influence on survival
according to Kaplan-Meier survival curve analysis, regardless
of the cut-off value in our study. Moreover, the stage was the
only significant factor affecting the overall survival. However,
cdc2 showed a lower expression in complete remission group
than in progressive disease group, which was statistically sig-
nificant (p=0.047). Although this fact suggests that cdc2 may
be a useful predictor for outcome of chemotherapeutic inter-
vention in malignant lymphoma, the standard percentage of
cdc2, which predicts chemotherapy response in non-Hodgkin’s
lymphoma, should be determined through prospective studies
with large numbers of patient group for clinical application.
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